Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Lymphoid 3Other hematologic neoplasm 2Myeloid 2Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia 1

Interventions

Cyclophosphamide 49fludarabine phosphate 42fludarabine 37Azacitidine 35Busulfan 30Whole-Body Irradiation 26Imatinib Mesylate 24Antilymphocyte Serum 24Tacrolimus 23Mycophenolic Acid 22Cytarabine 21Filgrastim 20Peripheral Blood Stem Cell Transplantation 17Methotrexate 17Melphalan 17Cyclosporine 16venetoclax 14thymoglobulin 14Granulocyte Colony-Stimulating Factor 14Thiotepa 12ruxolitinib 11Stem Cell Transplantation 11Decitabine 11Dasatinib 11Alemtuzumab 11nilotinib 10Radiotherapy 10Rituximab 9Cord Blood Stem Cell Transplantation 9ponatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × mocetinostat × Myeloid × Clear all
NCT00374296 2015-07-01

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Mirati Therapeutics Inc.

Phase 2 Terminated
35 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00666497 2015-05-08

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Mirati Therapeutics Inc.

Phase 2 Terminated
6 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡